Muramatsu Tomoki

ムラマツトモキ | Muramatsu Tomoki

Affiliation and department：

Research field (1)： Molecular biology

Research theme for competitive and other funds (8)：

2021 - 2024 Analysis of mechanisms of the hypoxic responses by BET proteins
2018 - 2021 Development of therapeutic miRNAs targeting BET family protein BRD4 for cancer
2018 - 2020 Exploring the transcriptional repressors of VEGFA by in vitro/in vivo high throughput screening
2015 - 2020 Establishment of novel concept for cancer diagnostics and therapeutics based on the systematic comprehension of cellular context in cancer
2015 - 2017 Analysis of mechanism of hypusine pathway in cancer

Show all

Papers (29)：

Chang Liu, Yasuyuki Gen, Kousuke Tanimoto, Tomoki Muramatsu, Jun Inoue, Johji Inazawa. Concurrent targeting of MAP3K3 and BRD4 by miR-3140-3p overcomes acquired resistance to BET inhibitors in neuroblastoma cells. Molecular Therapy - Nucleic Acids. 2021. 25. 83-92
Yasuyuki Gen, Tomoki Muramatsu, Jun Inoue, Johji Inazawa. miR-766-5p targets super-enhancers by downregulating CBP and BRD4. Cancer research. 2021
Koichi Nishino, Yasuhiro Yoshimatsu, Tomoki Muramatsu, Yasuhito Sekimoto, Keiko Mitani, Etsuko Kobayashi, Shouichi Okamoto, Hiroki Ebana, Yoshinori Okada, Masatoshi Kurihara, et al. Isolation and characterisation of lymphatic endothelial cells from lung tissues affected by lymphangioleiomyomatosis. Scientific reports. 2021. 11. 1. 8406-8406
Bo Xu, Tomoki Muramatsu, Johji Inazawa. Suppression of MET Signaling Mediated by Pitavastatin and Capmatinib Inhibits Oral and Esophageal Cancer Cell Growth. Molecular cancer research : MCR. 2020. 19. 4. 585-597
Elena Deryugina, Alexia Carré, Veronica Ardi, Tomoki Muramatsu, Jonas Schmidt, Christine Pham, James P Quigley. Neutrophil Elastase Facilitates Tumor Cell Intravasation and Early Metastatic Events. iScience. 2020. 23. 12. 101799-101799

ｍore...

MISC (45)：

村松智輝, 徐博, 稲澤譲治. 口腔・食道がんにおいてピタバスタチンはAKT、ERKのシグナルを抑制し、細胞増殖を阻害する. 日本癌学会総会記事. 2020. 79回. OE5-8
内藤諒, 村松智輝, 谷本幸介, 稲澤譲治. 統合的mRNA, miRNA発現情報を基盤とした独自のマイクロRNA標的遺伝子予測データベースの構築(Construction of an in-house microRNA-target prediction database based on an integrative mRNA-microRNA expression data). 日本癌学会総会記事. 2019. 78回. E-1063
村松智輝, 佐藤拓, 田邉稔, 稲澤譲治. 循環腫瘍細胞亜株(Panc-1-CTC)の発現解析から見出したTGFBIの機能解析(Identification and characterization of TGFBI in circulating tumor cell subline from pancreatic cancer cell line). 日本癌学会総会記事. 2019. 78回. P-1058
高川祐希, 玄泰行, 村松智輝, 原田浩之, 稲澤譲治. 機能的miRNAライブラリースクリーニングによる、BRD4を標的とする新規癌抑制型miRNAの同定(Function-based microRNA library screening identified novel tumor suppressive microRNAs targeting BRD4). 日本癌学会総会記事. 2019. 78回. P-1238
吉松康裕, 赤津裕一, 高橋直也, 紀室志織, 村松智輝, 桂彰宏, 間石奈湖, 鈴木洋, 稲澤譲治, 樋田京子, et al. 線維芽細胞増殖因子(FGF2)は腫瘍血管内皮細胞においてTGF-βによって誘導される内皮-筋線維芽移行を制御する(Fibroblast growth factor 2 regulates TGF-β-induced endothelial-to-myofibroblast transition of tumor endothelial cells). 日本癌学会総会記事. 2019. 78回. P-2280

ｍore...

Lectures and oral presentations (34)：

口腔・食道がんにおいてピタバスタチンはAKT、ERKのシグナルを抑制し、細胞増殖を阻害する
(日本癌学会総会記事 2020)
新規癌抑制型miRNAによるMYC標的核酸抗癌治療の可能性(Oligonucleotide therapeutics using a novel tumor-suppressive microRNA targeting MYC pathway)
(日本癌学会総会記事 2019)
扁平上皮がん細胞においてピタバスタチンはAKT、ERKの抑制を介して細胞増殖を阻害する(Pitavastatin inhibits the cell growth through the downregulation of AKT and ERK in squamous cell carcinoma)
(日本癌学会総会記事 2019)
線維芽細胞増殖因子(FGF2)は腫瘍血管内皮細胞においてTGF-βによって誘導される内皮-筋線維芽移行を制御する(Fibroblast growth factor 2 regulates TGF-β-induced endothelial-to-myofibroblast transition of tumor endothelial cells)
(日本癌学会総会記事 2019)
機能的miRNAライブラリースクリーニングによる、BRD4を標的とする新規癌抑制型miRNAの同定(Function-based microRNA library screening identified novel tumor suppressive microRNAs targeting BRD4)
(日本癌学会総会記事 2019)

ｍore...

Association Membership(s) (2)：

日本がん分子標的治療学会 , 日本癌学会

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page